The endothelium plays a crucial role in the pathogenesis of cardiovascular disease. Endothelial function is attenuated by the presence of different well known cardiovascular risk factors. Evaluation of endothelial vasodilator function serve as an index integrating the overall stress imposed by cardiovascular risk factors and reinforce the suggestion that endothelial dysfunction is an early marker of cardiovascular disease that precedes clinical manifestations. Angiotensin-converting enzyme inhibitors have been shown to reduce the cardiovascu-
Introduction
The endothelium is a complex endocrine and paracrine organ that affects vasodilation, smooth muscle cell proliferation, platelet aggregation, monocyte and leukocyte adhesion, and fibrinolysis. 1 The functional integrity of the endothelium is crucial to proportionate to the cardiovascular system vasodilator, antiatherosclerotic and antithrombotic effects through the secretion of vasoactive substances such as prostacyclin and particularly nitric oxide (NO).
1-3

Endothelial function and cardiovascular disease
Endothelial vasodilator function is attenuated by the presence of different well known cardiovascular risk factors such as hyperlipidaemia, diabetes mellitus, hypertension and smoking. 4 In consequence, attenuation of endothelial mediated vasodilatation could be considered as an early marker of cardiovascular disease (CVD) and could be an important tool to investigate cardiovascular pathophysiology.
Recently, a non-invasive method using high-resolution ultrasound has been developed to assess flow mediated dilation (FMD) of the brachial artery, which is modulated by the release of NO during reactive hyperaemia. 5, 6 Estimates of endothelial function by this test are remarkably stable over time, but no clear set of normal values has been developed. 7 Because of the different genetic background and variability in the distribution of CVD risk factors, normal values of FMD may differ among populations. 8 We have found in 253 normotensive healthy volunteers, that the mean %FMD was dependent on the presence of risk factors for CVD. Subjects with no risk factors had a mean %FMD of 13.74% (95% confidence interval (CI): 13.14, 14.35), while in those with at least one risk factor the mean was significantly lower: 7.40% (95% CI: 4.33, 9.91). 8 Obesity, smoking, and hypercholesterolaemia were the modifiable risk factors with the largest independently significant reduction effects on %FMD, as evaluated in the multivariate model. Obese subjects had a %FMD 4.60% units lower than non-obese subjects (95% CI: −6.50, −2.71). Regardless of the effect of other risk factors, smokers and hypercholesterolaemic subjects had a reduction of 4.45 (P Ͻ 0.001) and 3.67 (P Ͻ 0.001) units in %FMD as compared with non-smokers and nonhypercholesterolaemic subjects, respectively. 8 We did a receiver operating characteristic (ROC) analysis to identify the best %FMD cut-off point useful to identify subjects with and without cardiovascular risk factors. The area under the ROC curve was 83.28% (95% CI: 77.80, 88.77). The ROC plot suggested a cut-off point of 12 for %FMD. Sensitivity and specificity for this cut-off point were 76.7% and 66.1%, respectively. The positive predictive value for this cut-off point was 47.9%, while the negative predictive values reached 87.5%. We also explored the performance of other cut-off points, based on their validity and predictive capacity and selected the point at which the number of false-positive began to exceed the number of falsenegative test results. Based on this criterium, the best %FMD cut-off point was 10.4, which resulted in a sensitivity of 71.2% and a specificity of 77.2%. Positive and negative predictive values for this cutoff point were 55.9% and 86.9%, respectively. Using this cut-off point, endothelial dysfunction was 3.13 times more frequent in subjects with, than in subjects without cardiovascular risk factors (95% CI: 2.30, 4.25). 8 Similar analyses have been realised to evaluate if the %FMD is useful in identifying subjects with and without coronary artery disease. These analysis reported that %FMD was a sensitive and specific (71.3% and 81% respectively) screening test to predict the presence of coronary artery disease. 9 Moreover, our results showed that FMD measurements can be made with high accuracy and precision (Lin's correlation coefficient of 0.88), and very low bias (mean inter-observer difference of −0.30%).
8 These results clearly show that no invasive evaluation of endothelial vasodilator function may serve as an index integrating the overall stress imposed by CVD risk factors and reinforce the suggestion that endothelial dysfunction is an early marker of CVD that precedes clinical manifestations. 8, 10 An important body of evidence suggests that endothelial dysfunction is a generalised process that is not necessarily confined to vessels with overt atherosclerotic alterations. [4] [5] [6] [7] [8] [9] [10] This proposal is strengthened by the high correlation (Ͼ0.75) reported between the coronary vasomotor response and the peripheral endothelial function of the brachial artery evaluated by FMD. 11, 12 Recently, three different groups 10, 13, 14 have demonstrated that the diagnostic of endothelial dysfunction realised in coronary and peripheral arteries in patients with different stages of coronary artery disease is related with an increased incidence of an adverse long-term outcome of coronary heart disease.
Several studies have demonstrated that treatment of cardiovascular risk factors known to lead to endothelial dysfunction is associated with a decrease in cardiac events in both primary and secondary prevention studies, 15, 16 underscoring the concept that the reduction in cardiac events in this patient's population may be secondary to improvement in coronary endothelial function.
In conclusion, FMD is attractive as a non-invasive method to assess the integrity of vascular endothelial function and can be recommended as a screening test for the detection of patients at risk of CVD. It also can be used to assess short and longJournal of Human Hypertension term effects of therapeutic interventions on systemic endothelial function.
Angiotensin-converting enzyme (ACE) inhibitors and calcium antagonists as alternatives to improve endothelial dysfunction
A functional ACE system present in the vascular endothelium contributes to the regulation of adequate vascular biology. 17 ACE inhibitors have been shown to reduce cardiovascular mortality in patients with left ventricular dysfunction, acute myocardial infarction and also in patients at high risk of cardiovascular events. [18] [19] [20] Vanhoutte et al, 21 showed that ACE inhibition had beneficial effects on endothelial function in animal models. The TREND and BANFF Studies, carry out in humans, evaluated the effect of quinapril, a highly specific tissular ACE inhibitor on endothelial function, in resistance and conduit arteries respectively, and confirmed the beneficial effects of ACE inhibitors in reversing the endothelial dysfunction. 22, 23 Several studies have suggested that the mechanism by which the tissular ACE inhibition might improve the endothelial function involve the NO pathway. Accumulating bradykinin may lead to increased NO synthesis and activity. 24 Another potential mechanism involves the inhibition of the production of angiotensin II and as a consequence decrease formation of superoxide anion (O − 2 ). It is well known that angiotensin II stimulates the NADH/NAD(P)H oxidase of endothelial and smooth muscle cells.
25 Figure 1 shows the effects of highly specific tissular ACE inhibitors in restoring the balance on the endothelial production of NO and O − 2 . Recent evidence has shown that acute administration of calcium antagonists improves the abnormal coronary vasomotion response in hypertension, atherosclerosis and hypercholesterolaemia. 26, 27 In addition, amlodipine and nifedipine have been recently shown to increase the coronary vaso- 
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Journal of Human Hypertension dilation and also the NO production from canine microvessels. 28, 29 The potential mechanisms for this effect are not yet clear. Early in the characterisation of the L-arginine:NO pathway the crucial role of physiological calcium concentrations in the production of endothelial NO and the control of vascular tone was demonstrated. 3 More recently, it has been proposed that calcium-antagonists up-regulate the activity of endothelial NO synthase in vitro. 30 However, it has been demonstrated that in the endothelium the principal calcium channels are mechano activates. 31 Calcium antagonists act specifically in calcium channel voltage operates, so it is unlikely that these drugs perform any direct effect in the endothelial function. So, other mechanisms have been proposed to explain the effect of calcium antagonists in the endothelial function, as the antioxidant activity described for these compounds. Thus, amlodipine has been demonstrated to have antioxidant properties in atherosclerotic animal models, but its effect on endothelial function has not been extensively assessed in humans. 32 Recently, Anderson et al 23 reported that amlodipine did not improve reactive hyperaemic blood flow in peripheral arteries of patients with coronary disease in contrast to the improvement observed with quinapril.
In conclusion, the ACE inhibitors, especially those with high affinity with the endothelial ACE, show the best effects in reversing endothelial dysfunction, an activity that is related to accumulation of bradykinin. 33 The results with calcium antagonists are still controversial.
